ONL Therapeutics
PrivateLast Round
Series D
Sep 13, 2024
Total Funding Raised
$150.35M
Company Overview
ONL Therapeutics is a biopharmaceutical company that develops first-in-class therapeutics to protect and improve the vision of patients with retinal diseases and conditions.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
ONL Therapeutics Comparables
Compare ONL Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Astellas Pharma Inc. | 80% | |
| Aviceda Therapeutics | 80% | |
| NGM Biopharmaceuticals | 77% | |
ONL Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series D | Sep 13, 2024 | ||||
| VC Round | Mar 12, 2024 | ||||
| Series C | Aug 1, 2023 | ||||
| Series C | Mar 8, 2023 | ||||
| Series B | Dec 22, 2020 | ||||
Convertible Debt | Aug 15, 2019 |
Key People
Founding team and executive leadership
ONL Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Kaitai Capital | Series C, Series B |
| Hestia Investments | Series A |
| Biosciences Research & Commercialization Center | Convertible Debt, Series C, Series B, Series A |
| Michigan Investment in New Technology Startups | Convertible Debt, Series B, Series C, Series A |
| Mayewell Capital | Series C |
| Michigan Capital Network | Convertible Debt, Series B, Series C |
| Michigan Strategic Fund | Debt, VC Round, Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Nov 10, 2025
Presented at the FLORetina-ICOOR Congress 2025.
- Nov 10, 2025
Will present at the EYENOVATE conference.
ONL Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about ONL Therapeutics's valuation, stock price, and market status.